Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) granted 13,144 restricted stock units to nine newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

The awards were approved by the compensation committee with a grant date of December 17, 2025 and reported December 19, 2025, as an inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting each anniversary, subject to continuous employment on each vesting date.

Key Figures

RSU grant size 13,144 restricted stock units Granted to nine newly hired non-executive officers on December 17, 2025

Number of recipients 9 employees Newly hired non-executive officers receiving inducement RSUs

Vesting period 4 years RSUs vest with 25% on each anniversary of the grant date

Annual vesting rate 25% per year Portion of RSUs vesting on each grant date anniversary

Market Reality Check

$34.75 Last Close

Volume Volume 2,415,662 is 1.62x the 20-day average of 1,492,089 shares, indicating elevated trading activity before this filing. high

Technical Price at 33.50 is slightly below the 200-day MA of 33.61, with shares trading 27.96% below the 52-week high and 29.79% above the 52-week low.

Peers on Argus

Peers show mixed, mostly modest moves: XENE up 0.09%, NAMS up 2.45%, SRRK up 1.79%, while SLNO is down 1.52% and TLX is flat. With no momentum flags or same-day peer headlines, RARE’s setup appears more stock-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 24	Investor conferences	Positive	+2.3%	Participation in two early December 2025 healthcare investor conferences.
Nov 21	Inducement grant	Neutral	-2.4%	Grant of 18,180 RSUs to 12 new non‑executive officers under inducement plan.
Nov 04	Q3 2025 earnings	Positive	-3.0%	Q3 revenue growth to $159.9M, reaffirmed 2025 guidance, path to 2027 GAAP profitability.
Nov 04	Royalty sale deal	Positive	-3.0%	Sale of additional 25% Crysvita royalty interest to OMERS for $400M cash.
Oct 30	Clinical trial update	Positive	+1.7%	First patient dosed in Aurora GTX‑102 study and Aspire Phase 3 fully enrolled.

Pattern Detected

Recent value-creating clinical and financial updates (Aurora study progress, royalty sale, earnings) have sometimes been met with negative price reactions, while conference participation and clinical milestones drew more supportive responses.

Recent Company History

This announcement adds another small employment inducement grant to Ultragenyx’s recent stream of operational and strategic updates. In October 2025, the company reported first patient dosed in the Aurora GTX‑102 study and highlighted fully enrolled Phase 3 Aspire data expected in H2 2026. On November 4, 2025, Ultragenyx reported Q3 revenue of $159.9M and a $400M Crysvita royalty sale to OMERS. A prior inducement grant on November 16, 2025 saw a negative price reaction, underscoring some sensitivity to equity-based compensation news.

Market Pulse Summary

This announcement details a routine employment inducement grant of 13,144 restricted stock units to nine newly hired non‑executive officers, vesting over four years. It follows a period of significant updates, including Q3 revenue of $159.9M, a $400M Crysvita royalty transaction, and progress in the GTX‑102 program. Investors monitoring RARE may focus on how ongoing equity grants interact with the existing share base, upcoming late‑stage clinical readouts, and the company’s reiterated path toward GAAP profitability in 2027.

Key Terms

restricted stock units financial

"reported the grant of 13,144 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 13,144 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 17, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What did Ultragenyx (RARE) announce on December 19, 2025 about employee awards?

Ultragenyx announced a grant of 13,144 restricted stock units to nine newly hired non-executive officers.

When was the Ultragenyx inducement grant (RARE) dated and approved?

The awards had a grant date of December 17, 2025 and were approved by the compensation committee.

How do the Ultragenyx RSUs (RARE) vest for the new hires?

The RSUs vest over four years with 25% of shares vesting each anniversary, conditioned on continuous employment.

Under which plan and Nasdaq rule were Ultragenyx's (RARE) inducement awards granted?

They were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received RSUs in Ultragenyx's December 2025 inducement grant (RARE)?

Nine newly hired non-executive officers received the 13,144 restricted stock units.

Does the December 2025 RSU grant for Ultragenyx (RARE) change outstanding share count immediately?

The announcement reports an award of RSUs; it does not state any immediate issuance or change to outstanding shares.